Sep. 4 at 3:03 PM
$RNXT bullish thesis remains intact.
This isn’t just momentum anymore: RenovoCath revenue is accelerating, Phase III enrollment is complete, Nasdaq risk is resolved, PK/PD data support the TAMP mechanism, and the stock has now broken through the old
$1.75-
$1.93 warrant zone on huge volume.
Technical roadmap:
$2.00-
$2.10 = major support
$2.59 = breakout level
$2.59 =
$3.00-
$3.50 becomes realistic
Strong Q3 commercial data = potential
$4+ re-rating
My view:
$3-
$3.50 is achievable near term if the breakout confirms, with
$4-
$5 plausible into 2027 as commercialization scales and TIGeR-PaC approaches readout.
The key is that RNXT is transitioning from “distressed microcap” valuation toward “commercial + Phase III optionality.”
Still early.
$RNXT $XBI $IBB
